Tele Norte Leste Analyst Report: Vivo Participacoes Big Pharma Playing Rough with Generic Drugmakers As analyst Brian Laegeler wrote in his recent analysis of generic drug-maker Teva Pharmaceuticals TEVA, big pharma is taking a novel new
to our fair value estimate. At these prices, there should be enough value to go around for all parties involved. Brian Laegeler Angiotech Pharmaceuticals Highlights Pipeline (Maintaining) Angiotech Pharmaceuticals ANPI reported decent first
manufacturing cost advantage has dissipated with the appreciation of the Canadian dollar. While Morningstar analyst Brian Laegeler believes the business could be worth as much as $20 per share to a large competitor, the family controls almost
Serono SRA, Biogen's competitor in the multiple sclerosis market. While Tysabri may lure some patients away from Serono's Rebif, restrictive FDA safety guidelines reduce Tysabri's threat. Brian Laegeler contributed to this note.